John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Show notes

Speaker 3: (00:32)
Would you provide a little background on yourself, Dr. Mills?

Speaker 3: (01:19)
Dr. Dubey?

Speaker 3: (02:07)
Can you give a brief overview of our demyelinating test and recommended use?

Speaker 3: (03:52)
Can you discuss how this new test will assist in a patient's journey?

Speaker 3: (05:46)
Can you tell us some of the unique features of this test?

Speaker 3: (08:09)
Dr. Dubey, as a neurologist, how does this test set us apart in the market?

Speaker 3: (11:05)
Could you summarize the benefits of having both a demyelinating panel and an axonal panel?

Speaker 3: (11:40)
Why should a patient have an axonal or demyelinating test versus a sensory and motor test for peripheral neuropathy?

In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by special guests Bernard Rubin, D.O., MPH, chief medical officer of Progentec Diagnostics, and Melissa Munroe, M.D., Ph.D., chief scientific officer and principal investigator of Progentec Diagnostics. They discuss Mayo Clinic Laboratories’ suite of innovative lupus testing, offered in collaboration with Progentec Diagnostics, for patients affected by systemic lupus erythematosus (SLE).

Their discussion includes:

• The Progentec aiSLE® DX Lupus Flare Risk Index that uses an algorithm to calculate a flare risk index, which assigns a score based on a patient's risk of a forthcoming lupus flare.
• The Progentec aiSLE® DX Lupus Disease Activity Index that characterizes a patient’s current disease activity into low, moderate, or active states.
• How these two tests were developed and for whom they are recommended.
• Why these tests are a significant development and how they enhance the quality of life for patients living with SLE.

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

Speaker 3: (00:32)
Would you tell us a little bit about yourself and your history with this testing?

Speaker 3: (01:25)
Would you tell us a little more about this assay?

Speaker 3: (04:57)
Which patients should have this testing and when should it be performed?

Speaker 3: (05:30)
What alternative tests exist and how do they compare?

Speaker 3: (06:28)
How are the results used in patient care?